Prostate Cancer: Innovations in Diagnosis and Risk Stratification

Dear Colleagues,

Prostate cancer management is undergoing a paradigm shift, driven by groundbreaking advances in molecular imaging and targeted therapies. The integration of Prostate Specific Membrane Antigen (PSMA)-targeted diagnostics, particularly with nuclear medicine, is revolutionizing diagnostic and therapeutic approach—from initial detection and staging to the treatment of advanced disease. This evolution is refining risk stratification, personalizing therapeutic pathways, and uncovering new challenges and opportunities.

This Special Issue of Diagnostics aims to capture the full spectrum of this transformation. We seek to explore not only the technological triumphs but also the critical nuances of modern prostate cancer care. This includes the evolving role of hormonal therapies, the pitfalls and limitations of current management strategies (from diagnostic inaccuracies to complexities in multimodal therapy), and the gaps that exist between clinical practice and established guidelines. Furthermore, we encourage submissions that address atypical presentations of the disease, which can complicate diagnosis and treatment, and contributions that discuss how novel molecular insights are bridging prostate cancer with other malignancies.

We invite researchers and clinicians to submit original research articles, comprehensive reviews, insightful case reports, and short communications on topics including, but not limited to, the following:

• Molecular Targets in Prostate Cancer: Discovery, validation, and clinical application of new biomarkers;
• Imaging Targets in Prostate Cancer: Discovery, validation, and clinical applications of imaging targets;
• Overlaps in Molecular Targets in Prostate Cancer and Other Cancers: Exploring shared pathways and diagnostic/therapeutic implications;
• Therapeutics Based on Molecular Targets: PSMA-targeted radioligand therapy, antibody-drug conjugates, and other novel agents;
• Innovations in Diagnostics: Advanced imaging techniques, AI-assisted analysis, and liquid biopsies;
• Refining Risk Stratification: Integrating genomic and clinical data for improved prognostication;
• Novel Hormonal Therapy Combinations and Resistance Mechanisms;
• Pitfalls and Challenges in Current Management: From over-diagnosis to sequencing of therapies in castration-resistant prostate cancer (CRPC);
• Guidelines Gaps and Atypical Presentations: Case studies and analyses that challenge conventional wisdom and highlight areas for guideline evolution.

Dr. Biren Saraiya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.